Spero Therapeutics, Inc.

NasdaqGS:SPRO Voorraadrapport

Marktkapitalisatie: US$63.8m

Spero Therapeutics Beheer

Beheer criteriumcontroles 2/4

Spero Therapeutics' CEO is Sath Shukla, appointed in Aug 2023, has a tenure of 1.25 years. total yearly compensation is $2.02M, comprised of 25.9% salary and 74.1% bonuses, including company stock and options. directly owns 0.069% of the company’s shares, worth $44.03K. The average tenure of the management team and the board of directors is 2 years and 10.5 years respectively.

Belangrijke informatie

Sath Shukla

Algemeen directeur

US$2.0m

Totale compensatie

Percentage CEO-salaris25.9%
Dienstverband CEO1.3yrs
Eigendom CEO0.07%
Management gemiddelde ambtstermijn2yrs
Gemiddelde ambtstermijn bestuur10.5yrs

Recente managementupdates

Recent updates

There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding

Nov 02
There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding

Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price

Jul 15
Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Apr 23

Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%

Mar 12
Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Jan 02
Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates

May 18
Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates

Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth

Apr 17
Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth

Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%

Apr 13
Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%

We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Apr 05
We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value

Oct 03

Spero Therapeutics appoints Kamal Hamed MD CMO

Sep 15

Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate

Sep 06

Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M

Aug 10

We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate

Jul 04
We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate

We're Hopeful That Spero Therapeutics (NASDAQ:SPRO) Will Use Its Cash Wisely

Mar 17
We're Hopeful That Spero Therapeutics (NASDAQ:SPRO) Will Use Its Cash Wisely

Analyse CEO-vergoeding

Hoe is Sath Shukla's beloning veranderd ten opzichte van Spero Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

US$17m

Mar 31 2024n/an/a

US$23m

Dec 31 2023US$2mUS$524k

US$23m

Sep 30 2023n/an/a

-US$2m

Jun 30 2023n/an/a

-US$10m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022US$2mUS$478k

-US$46m

Sep 30 2022n/an/a

-US$102m

Jun 30 2022n/an/a

-US$113m

Mar 31 2022n/an/a

-US$103m

Dec 31 2021US$2mUS$441k

-US$90m

Compensatie versus markt: Sath's total compensation ($USD2.02M) is above average for companies of similar size in the US market ($USD655.65K).

Compensatie versus inkomsten: Sath's compensation has been consistent with company performance over the past year.

CEO

Sath Shukla (51 yo)

1.3yrs

Tenure

US$2,024,647

Compensatie

Mr. Satyavrat Shukla, also known as Sath, C.F.A., has been President, Chief Executive Officer and Director at Spero Therapeutics, Inc. since August 1, 2023. He had been the Chief Financial Officer of Spero...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Ankit Mahadevia
Co-Founder & Chairman of the Board11.2yrsUS$2.39m0.43%
$ 275.5k
Satyavrat Shukla
President1.3yrsUS$2.02m0.069%
$ 44.0k
Timothy Keutzer
Chief Operating Officer1.8yrsUS$1.44m0.13%
$ 79.8k
Esther Rajavelu
CFO, Chief Business Officer & Treasurer1.3yrsgeen gegevensgeen gegevens
James Brady
Chief Human Resource Officer3yrsgeen gegevensgeen gegevens
Kamal Hamed
Chief Medical Officer2.2yrsgeen gegevens0.22%
$ 143.3k

2.0yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: SPRO's management team is not considered experienced ( 2 years average tenure), which suggests a new team.

Bestuursleden

NaamPositieTenureCompensatieEigendom
Ankit Mahadevia
Co-Founder & Chairman of the Board11.2yrsUS$2.39m0.43%
$ 275.5k
Satyavrat Shukla
President1.3yrsUS$2.02m0.069%
$ 44.0k
Frank Thomas
Independent Director7.3yrsUS$88.83k0.028%
$ 17.7k
Milind Deshpande
Independent Director10.8yrsUS$105.70k0.058%
$ 37.1k
Eric Gordon
Scientific Advisors10.5yrsgeen gegevensgeen gegevens
George Drusano
Clinical Advisor10.5yrsgeen gegevensgeen gegevens
Steven Gilman
Scientific Advisorno datageen gegevensgeen gegevens
Patrick V. J. Vink
Lead Independent Director9.2yrsUS$93.19k0.028%
$ 17.7k
Gordon Archer
Clinical Advisor10.5yrsgeen gegevensgeen gegevens
David Livermore
Scientific Advisorno datageen gegevensgeen gegevens
Paul Ambrose
Clinical Advisor10.5yrsgeen gegevensgeen gegevens
Cynthia Smith
Independent Director5.7yrsUS$73.20k0.028%
$ 17.7k

10.5yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: SPRO's board of directors are seasoned and experienced ( 10.5 years average tenure).